Thieno[2,3-b]pyridine derivatives as epac inhibitors and their pharmaceutical uses

A method for treating and/or preventing a disease wherein the Epac protein is involved, wherein said disease is 5 a cardiac disease selected from the group consisting of:

• cardiac hypertrophy, cardiac arrhythmias, valvulopathies, diastolic dysfunction, chronic heart failure, ischemic heart failure, myocardial ischemia, reperfusion injury, myocarditis, hypertrophic and dilated cardiomyopathies, said method comprising administering to a patient in need thereof a pharmaceutical acceptable amount of a compound of formula (I), said compound having the following formula (I):
• wherein:
• R1 is selected from the group consisting of:
• H;
• (C2-C20)alkyl;
• (C3-C10)cycloalkyl;
• 3-10 membered heterocycloalkyl;
• (C6-C10)aryl;
• and
• 5-10 membered heteroaryl;
• wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally substituted;
• R2 is selected from the group consisting of:
• H;
• (C1-C20)alkyl;
• (C3-C10)cycloalkyl;
• 3-10 membered heterocycloalkyl;
• (C6-C10)aryl;
• and
• 5-10 membered heteroaryl;
• or R2 and R4 together with the carbon atoms carrying them form a (C3-C10)cycloalkyl group;
• wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally substituted;
• R3 is selected from the group consisting of:
• H;
• (C3-C10)cycloalkyl;
• 3-10 membered heterocycloalkyl;
• (C6-C10)aryl;
• and
• 5-10 membered heteroaryl;
• wherein said cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally substituted;
• and
• R4 is selected from the group consisting of:
• H, —OH, —NRxRy and —C(O)ORz, Rx, Ry and Rz being independently of each other H or a (C1-C10)alkyl;
• or R2 and R4 together with the carbon atoms carrying them form a (C3-C10)cycloalkyl group;
• or its pharmaceutically acceptable salt, hydrate or hydrated salt or its polymorphic crystalline structure, racemate, diastereomer or enantiomer.